Correlation Between Lumos Pharma and AN2 Therapeutics
Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lumos Pharma and AN2 Therapeutics, you can compare the effects of market volatilities on Lumos Pharma and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and AN2 Therapeutics.
Diversification Opportunities for Lumos Pharma and AN2 Therapeutics
0.39 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Lumos and AN2 is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and AN2 Therapeutics go up and down completely randomly.
Pair Corralation between Lumos Pharma and AN2 Therapeutics
Given the investment horizon of 90 days Lumos Pharma is expected to under-perform the AN2 Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Lumos Pharma is 9.91 times less risky than AN2 Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The AN2 Therapeutics is currently generating about 0.29 of returns per unit of risk over similar time horizon. If you would invest 108.00 in AN2 Therapeutics on September 4, 2024 and sell it today you would earn a total of 52.00 from holding AN2 Therapeutics or generate 48.15% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Lumos Pharma vs. AN2 Therapeutics
Performance |
| Timeline |
| Lumos Pharma |
| AN2 Therapeutics |
Lumos Pharma and AN2 Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Lumos Pharma and AN2 Therapeutics
The main advantage of trading using opposite Lumos Pharma and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.| Lumos Pharma vs. Candel Therapeutics | Lumos Pharma vs. Cingulate Warrants | Lumos Pharma vs. Unicycive Therapeutics | Lumos Pharma vs. Cardio Diagnostics Holdings |
| AN2 Therapeutics vs. Aerovate Therapeutics | AN2 Therapeutics vs. Adagene | AN2 Therapeutics vs. Acrivon Therapeutics, Common | AN2 Therapeutics vs. Rezolute |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |